Bristol Myers Squibb (BMY) risk factors

Bristol Myers Squibb highlights increased focus on asset impairment risks from recent acquisitions like Mirati, Karuna, and RayzeBio. Royalty income increased to $2.7 billion in 2025, but faces future declines. The company acknowledges ongoing risks from supply chain geopolitical factors and debt levels.

Pricing pressures and reimbursement controls in the U.S. and EU threaten profit margins across key pharmaceutical portfolios. Heavy reliance on major branded drugs like Eliquis, Opdivo, Orencia, and Yervoy creates revenue concentration risk. Extensive debt from large acquisitions including Celgene, MyoKardia, Mirati, Karuna, and RayzeBio impacts financial flexibility.